Cutaneous T-cell Lymphoma

In both cases, the epidermotropic infiltrate was CD8-positive T-cell dominant, accompanied by scarce FOXP3-positive cells and increased expression of CXCL10 together with CCL19. These shared features support the concept that a Tc1-associated cytotoxic immune milieu, accompanied by scarce FOXP3-positive cells, may be associated with hypopigmentation in hypopigmented MF, irrespective of the age at clinical presentation.

SII is a cost-effective and accessible prognostic marker for advanced-stage MF and may aid in identifying high-risk patients who benefit from closer monitoring or earlier intervention.

Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine...These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.

However, further research, for example, using multi-omics approaches, are needed to provide a more comprehensive picture of the ECP-induced secretome and to identify relevant factors that could contribute to ECP's therapeutic effects. ECP induces the release of different pro/anti-inflammatory factors in different preexisting conditions that determine different DC maturation status and immunomodulatory effects.

Blocking IL-31RA with nemolizumab or targeting OSMRβ with vixarelimab has led to clinically significant improvements in itch severity, patient-reported quality of life, and sleep disturbance. Together, these findings suggest that the shared components of the IL-31 and OSM pathways, including OSMRβ and JAK1-STAT3, provide us with a big picture framework for understanding itch pathogenesis in chronic pruritic dermatoses and may help guide therapeutic strategies in the future.

The patient responded partially to cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone (CHOEP) chemotherapy and achieved a complete metabolic response after second-line chemotherapy consisting of dexamethasone, high-dose cytarabine, and carboplatin (DHAC) followed by BEAM-ASCT consolidation. This case highlights diagnostic and therapeutic challenges in atypical presentations of PC-ALCL.

The diagnostic overlap between AD and mycosis fungoides (the most common CTCL) complicates assessment. We examine evidence regarding dupilumab safety and CTCL risk specifically in pediatric patients, incorporating recently presented long-term open-label extension data, and provide recommendations for monitoring, distinguishing AD from CTCL, and counseling families navigating this complex topic.

The patient responded favorably to electron beam radiotherapy. This case underscores the importance of early biopsy in atypical or treatment-refractory ulcers and highlights the diagnostic relevance of recognizing rare variants such as the angiocentric subtype.

For multifocal or relapsed disease, brentuximab vedotin demonstrates the most robust prospective data and has reshaped the treatment landscape; however, alternative systemic therapies, including methotrexate and retinoids, remain relevant in selected patients. Overall, current management is supported largely by non-randomized data, and key gaps remain in risk stratification, optimal sequencing of therapies, and management of uncommon aggressive variants.

The main toxicities include grade 1-2 cytokine release syndrome and rare hematologic complications, while immune effector cell-associated neurotoxicity syndrome is uncommon. Clinical translation remains limited and requires larger studies to improve efficacy and define safety profiles.

P1/2, N=13, Active, not recruiting, City of Hope Medical Center | Trial completion date: Feb 2026 --> Feb 2027

This pharmacovigilance study detected neoplasm-related disproportionality signals for anti-Type 2 biologics. Causality cannot be established due to spontaneous reporting limitations. Clinicians should be aware of these disproportionality signals and maintain vigilance during long-term clinical management of patients receiving anti-Type 2 biologic therapy to ensure optimal patient safety.